Biotech Values

[Bickema]

Good question. LLY didn't sue upon notification of EGRX's 505b2 application, which would have afforded LLY an automatic 30-month stay on FDA approval of EGRX's product. So, I'm not sure how LLY intends to play this.

What benefit would LLY gain by passing up the 30 month stay and suing either now or after approval assuming there is a benefit and assuming Eagle gains approval

Also would you be shocked if Eagle scrapped its pursuit of EHS indication for Ryanodex, just curious? Thanks